These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Depo-Provera: just another contraceptive?
    Author: Jones M.
    Journal: Fertil Contracept; 1978 Apr; 2(2):26-9. PubMed ID: 12336094.
    Abstract:
    The lack of approval of Depo-Provera, the injectable contraceptive, by the United States and Britain has cast some doubts about its safety despite the fact that it has been used with increasing success and with no evidence of serious medical side effects for l0 years in the 70 or so European and developing countries where it is widely available. Medically, injectables are very effective. Depo-Provera has a pregnancy rate of 0.25/l00 woman years on the standard dosage of l50 mg per 3-monthly injection. Depo-Provera works by usually suppressing ovulation, increasing the viscosity of the cervical mucus, and causing changes in the endometrium, rendering it less suitable for implantation of the egg. The major side effects associated with Depo-Provera are weight gain and menstrual disturbance -- irregular or heavy bleeding and amenorrhea. Despite the lack of evidence of breast or cervical cancer or permanent impairment of fertility in the clinical studies that have been conducted, it is doubts in these areas which have delayed the acceptance of injectables in the United States and Great Britain. The doubters cite in particular the studies of Depo-Provera conducted by the U.S. Food and Drug Administration in the late l960's showing the development of breast nodules in beagle bitches. The prolonged controversy and frequent adverse publicity surrounding the use of Depo-Provera have made it difficult to objectively assess women's reactions. The response of 3 women using Depo-Provera is reported.
    [Abstract] [Full Text] [Related] [New Search]